Completed PHASE4 INTERVENTIONAL 1-arm NCT00771498

An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin (A06-295)

An Evaluation of the Pharmacological Interaction of Lopinavir 800mg - Ritonavir 200mg Combination and Rifampin in Subjects Presenting Tuberculosis, With Contraindication for Antiretroviral Regimens Including Efavirenz

Sponsor: Abbott

Conditions HIV Infection Tuberculosis

Interventions Lopinavir

Updated 6 times since 2017 Last updated: May 15, 2015 Started: Nov 30, 2008 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates HIV Infection and Tuberculosis and is currently completed. Abbott leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Oswaldo Cruz Foundation

Data source: Oswaldo Cruz Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rio de Janeiro, Brazil
• Vitória, Brazil